- Home
- PEN vs AXSM Comparison
PEN vs AXSM Comparison
Compare PEN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEN | AXSM |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 12.0B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PEN | AXSM |
|---|---|---|
| Price | $318.39 | $244.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 17 |
| Target Price | ★ $360.14 | $211.12 |
| AVG Volume (30 Days) | 362.8K | ★ 848.9K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1155.56 | 38.56 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $1,403,665,000.00 | N/A |
| Revenue This Year | $14.34 | $57.24 |
| Revenue Next Year | $13.71 | $55.88 |
| P/E Ratio | $388.48 | ★ N/A |
| Revenue Growth | ★ 17.50 | N/A |
| 52 Week Low | $221.26 | $96.09 |
| 52 Week High | $362.41 | $260.19 |
Technical Indicators
Market Signals| Indicator | PEN | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 56.60 |
| Support Level | $317.81 | $236.44 |
| Resistance Level | $322.24 | $260.19 |
| Average True Range (ATR) | 2.40 | 8.34 |
| MACD | 0.29 | -1.78 |
| Stochastic Oscillator | 53.86 | 33.14 |
Price Performance
Historical ComparisonAbout PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.